glomerular disease
Advertisement
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Several genetically predicted environmental factors increase the risk of IgAN and membranous nephropathy, a study found.
An analysis Identified SIRT1, BAG3, COKN1A and FOS as potential autophagy-related biomarkers for IgAN.
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy to help with risk stratification.
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS.
The FDA has granted Priority Review to pegcetacoplan to treat C3 glomerulopathy and primary IC-MPGN.
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Research compared the effects of sparsentan and irbesartan on proteinuria remission in focal segmental glomerulosclerosis.
NOBLE examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.
Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.